Skip to content
Kalpvruksh Markets
Offline Log in

MARKSANSNSEOffline

MARKSANS PHARMA · INE750C01026 · Small Cap · #599
313.75+12.10 (+4.01%)last close · 05 Nov 2026
Prev close
301.65
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹8,801 cr
52-week range · to 05 Nov 2026156.89347.6

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

MARKSANS is 10% below its 52-week high, above its 200-day average — a Small Cap company, #599 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 200-day averages · below its 50-day average · 10% below its 52-week high
  • +18.5% vs Nifty 500
  • traded value 1.2× usual · delivery 42% vs 39% usual
  • FPI +1.6 pp · DII −0.7 pp · MF schemes in Sept 2026: 4 bought, 8 cut · no promoter pledge · insiders net bought ₹0 cr in 3 months · quarter ended 2026-09-30
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹8,801 cr
Rank
#599
Cap band
Small Cap
Nearest cut-off — Mid / Small
−74.26% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.8×
median 5,54,413
Delivered
9,72,562
Of volume
44%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week−0.5%−6.0 pts—
1 month−3.3%−7.5 pts—
3 months+15.9%+18.5 pts—
6 months+59.9%+59.3 pts—
1 year+71.0%+75.6 pts—

Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+2.3%
above
vs 50-day average
−2.0%
below
vs 200-day average
+29.3%
above
ATR (14)
4.1%
typical daily range
Volatility
40%
1 month, annualised
Beta
1.19
vs Nifty 500, 1 year
Traded value
1.2×
vs usual
Delivery
42%
usual 39%
From the 52-week high
−9.7%
place in range 82% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters43.9%43.9%43.9%43.9%
FPI8.1%16.8% +8.617.5% +0.719.1% +1.6
Mutual funds4.4%4.7% +0.34.4% −0.33.7% −0.6
Other DII1.5%1.9% +0.41.8% −0.11.8%
Individuals29.0%28.3% −0.728.0% −0.327.1% −1.0
Others13.1%4.5% −8.64.4%4.5% +0.1

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
2,47,508
Individuals
2,38,175

Indian passive funds’ stake

2026-06-30

Of free float
0.24%
Of all shares
0.13%
Schemes
9
Days to unwind
0.3
at 100% of volume

6,05,053 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
23
9 index · 14 active
Bought more
4
Sold some
16
FundSharesChangeDid
Unifi Flexi Cap Fund-Reg(G)Active+1,09,873+91.5%bought
Kotak Healthcare Fund-Reg(G)Active+1,00,000+20.0%bought
Bandhan Small Cap Fund-Reg(G)Active+2,19,827+6.6%bought
UTI Retirement FundActive−2,76,930−34.4%sold
UTI Multi Cap Fund-Reg(G)Active−4,00,000−25.0%sold
UTI Aggressive Hybrid Fund-Reg(G)Active−5,31,393−22.7%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 26192280−7.1%₹282 cr
Aug 26170830−3.5%₹303 cr
Jul 26171390−8.8%₹252 cr
Jun 261610130−11.2%₹292 cr
May 26151461−2.3%₹297 cr
Apr 26150520+0.7%₹228 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
Bought ₹0 (3)
Sold ₹0 (1)
Others
No market buy or sell
Latest 4 of 6 disclosures
0 selected
11 Sept 2026Merrill Jean SaldanhaDirectors Immediate RelativeBuy63,273₹00.00%Gift
11 Sept 2026Marise Ann SaldanhaDirectors Immediate RelativeBuy20,000₹00.00%Gift
11 Sept 2026Schenelle Megan SaldanhaDirectors Immediate RelativeBuy1,45,000₹00.00%Gift
11 Sept 2026Sandra SaldanhaDirectorSell2,28,273₹00.00%Gift

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Marksans Pharma Limited has submitted to the Exchange, unaudited financial results for the quarter and half year ended September 30, 2026.
    04 Nov 2026
  • Board outcome
    Marksans Pharma Limited has submitted to the Exchange, the unaudited financial results for the quarter ended Jun 30, 2026.
    12 Aug 2026
  • Board outcome
    Outcome of Board Meeting-XBRL MARKSANS PHARMA LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 26-May-2026 for Dividend
    06 Jul 2026
  • Board outcome
    Marksans Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 03, 2026.
    03 Jul 2026
  • Credit rating
    Marksans Pharma Limited has informed the Exchange that India Ratings and Research has revised the outlook for the Company s bank loan facilities to Positive from Stable
    09 Jun 2026
  • Board outcome
    Outcome of Board Meeting-XBRL MARKSANS PHARMA LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 26-May-2026 for Dividend
    27 May 2026
  • Bulk deal: SELL
    43,49,697 at ₹313.4 — MICROCURVES TRADING PRIVATE LIMITED
    12 Aug 2026
  • Bulk deal: BUY
    43,49,697 at ₹313.24 — MICROCURVES TRADING PRIVATE LIMITED
    12 Aug 2026

Latest shown; 9 in six months on all disclosures.

MARKSANS: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
RecentDividend₹0.9Final20 Aug 202620 Aug 2026
EarlierDividend₹0.8Final01 Aug 202501 Aug 2025
EarlierDividend₹0.6Final17 Sept 202417 Sept 2024
EarlierDividend₹0.5Final07 Jun 202307 Jun 2023
EarlierDividend₹0.25Final19 Aug 202223 Aug 2022
EarlierDividend₹0.25Final15 Sept 202117 Sept 2021

6 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.